S-8 1 gray-s8.htm S-8 gray-s8.htm

 

As filed with the Securities and Exchange Commission on March 19, 2021

Registration No. 333-

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

GRAYBUG VISION, INC.

(Exact name of Registrant as specified in its charter)

 

 

Delaware

 

452120079

(State or other jurisdiction of

 

(I.R.S. Employer

incorporation or organization)

 

Identification Number)

 

 

 

275 Shoreline Drive, Suite 450

 

 

Redwood City, CA

 

94065

(Address of Principal Executive Offices)

 

(Zip Code)

 

2020 Equity Incentive Plan

 

(Full title of the plans)

Frederic Guerard

Chief Executive Officer

Graybug Vision, Inc.

275 Shoreline Drive, Suite 450

Redwood City, CA 94065

(650) 487-2800

(Name, address, and telephone number, including area code, of agent for service)

Please send copies of all communications to:

 

Effie Toshav, Esq.

Robert A. Freedman, Esq.

Julia Forbess, Esq.
Fenwick & West LLP
555 California Street, 12th Floor

San Francisco, California 94104
(415) 875-2300

 

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

 

Accelerated filer

 

 

 

 

 

Non-accelerated filer

 

 

Smaller reporting company

 

 

 

 

 

 

 

 

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

 


 

CALCULATION OF REGISTRATION FEE

 

 

 

 

 

 

Title of Securities

to be Registered

Amount to be

Registered(1)

Proposed Maximum

Offering Price

Per Share

Proposed Maximum

Aggregate Offering

Price

Amount of

Registration

Fee

Common Stock, $0.0001 par value per share

1,048,963(2)

$8.42(3)

$8,832,269.00

$964.00

(1)

Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of the Registrant’s common stock that becomes issuable in respect of the securities identified in the above table by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without the receipt of consideration that increases the number of the Registrant’s outstanding shares of common stock.

(2)

Represents additional shares to be registered and available for grant under the 2020 Equity Incentive Plan (“2020 Plan”) resulting from the annual 5% automatic increase in the number of authorized shares available for issuance under the 2020 Plan.

(3)

Estimated in accordance with Rules 457(c) and 457(h) of the Securities Act solely for the purpose of calculating the registration fee. The proposed maximum offering price per share of $8.42 was computed by averaging the high and low prices of a share of Registrant’s common stock as reported on The Nasdaq Global Market on March 15, 2021.

 

 


 

REGISTRATION OF ADDITIONAL SHARES

PURSUANT TO GENERAL INSTRUCTION E

Graybug Vision, Inc. (the “Registrant”) is filing this Registration Statement with the Securities and Exchange Commission (the “Commission”) to register 1,048,963 additional shares of common stock available for issuance under the Registrant’s 2020 Plan, pursuant to the provision of the 2020 Plan providing for an annual 5% automatic increase in the number of shares reserved for issuance.

In accordance with General Instruction E of Form S-8, and only with respect to the common stock issuable under the 2020 Plan and the Purchase Plan, this Registration Statement hereby incorporates by reference the contents of the Registrant’s Registration Statement on Form S-8 filed with the Commission on September 25, 2020 (Registration No. 333-249033), to the extent not superseded hereby.

 


 

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 3. Incorporation of Documents by Reference.

The following documents filed by the Registrant with the Commission pursuant to the Securities Act and the Securities Exchange Act of 1934, as amended (the “Exchange Act”) are incorporated herein by reference:

 

(a)

the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Commission on March 5, 2021 pursuant to Section 13 of the Exchange Act;

 

(b)

all other reports filed pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the Registrant’s Annual Report on Form 10-K referred to in (a) above; and

 

(c)

the description of the Registrant’s common stock contained in the Registrant’s registration statement on Form 8-A (File No. 001-39538) filed on September 21, 2020 under Section 12(b) of the Exchange Act, including any amendment or report filed for the purpose of updating such description.

All documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing such documents, except as to specific sections of such documents as set forth therein. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement.

Item 5. Interests of Named Experts and Counsel.

Not applicable.

Item 8. Exhibits.

The following exhibits are filed herewith:

 

Exhibit

 

 

 

Incorporated by Reference

 

Filed

Number

 

Exhibit Description

 

Form

 

File No.

 

Exhibit

 

Filing Date

 

Herewith

 

 

 

 

 

 

 

 

 

 

 

 

 

4.1

 

Restated Certificate of Incorporation of the Registrant

 

10-Q

 

001-39538

 

3.1

 

11/12/2020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

4.2

 

Restated Bylaws of the Registrant

 

10-Q

 

001-39538

 

3.2

 

11/12/2020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

4.3

 

Form of Registrant’s Common Stock certificate

 

S-1/A

 

333-248611

 

4.1

 

9/21/2020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

5.1

 

Opinion of Fenwick & West LLP

 

 

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

23.1

 

Consent of Fenwick & West LLP (contained in Exhibit 5.1)

 

 

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

23.2

 

Consent of Independent Registered Public Accounting Firm

 

 

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

24.1

 

Power of Attorney (included on the signature page to this Registration Statement)

 

 

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

99.1

 

2020 Equity Incentive Plan and forms of award agreements thereunder

 

S-1/A

 

333-248611

 

10.3

 

9/21/2020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

99.2

 

2020 Employee Stock Purchase Plan and forms of award agreements thereunder

 

S-1/A

 

333-248611

 

10.4

 

9/21/2020

 

 

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Redwood City, State of California, on this 19th day of March, 2021.

GRAYBUG VISION, INC.

 

 

By:

/s/ Frederic Guerard, Pharm.D.

 

 

Frederic Guerard, Pharm.D.

 

 

Chief Executive Officer and President

 

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Frederic Guerard  and Robert S. Breuil, and each of them, as his or her true and lawful attorney-in-fact and agent with full power of substitution, for him or her in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

 

Name

 

Title

 

Date

 

 

 

 

 

/s/ Frederic Guerard

 

Chief Executive Officer and Director

 

March 19, 2021

Frederic Guerard, Pharm.D.

 

(Principal Executive Officer)

 

 

 

 

 

 

 

/s/ Robert S. Breuil

 

Chief Financial Officer

 

March 19, 2021

Robert S. Breuil

 

(Principal Financial and Accounting Officer)

 

 

 

 

 

 

 

/s/ Christy Shaffer

 

Chairperson, Director

 

March 19, 2021

Christy Shaffer, Ph.D.

 

 

 

 

 

 

 

 

 

/s/ Christina Ackermann

 

Director

 

March 19, 2021

Christina Ackermann

 

 

 

 

 

 

 

 

 

/s/ Eric Bjerkholt

 

Director

 

March 19, 2021

Eric Bjerkholt

 

 

 

 

 

 

 

 

 

/s/ Gerald Cagle

 

Director

 

March 19, 2021

Gerald Cagle, Ph.D.

 

 

 

 

 

 

 

 

 

/s/ Julie Eastland

 

Director

 

March 19, 2021

Julie Eastland

 

 

 

 

 

 

 

 

 

/s/ Hansoo Michael Keyoung

 

Director

 

March 19, 2021

Hansoo Michael Keyoung, M.D., Ph.D.